Recombinant Human CD40L/CD154 protein (His Tag)

Species

Human

Purity

>95 %, SDS-PAGE

Tag

His Tag

Activity

EC50: 17-68 ng/mL

Cat no : Eg0054



Product Information

Purity >95 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Human CD40L (His tag) at 2 μg/mL (100 μL/well) can bind Human CD40 (Myc tag, His tag) with a linear range of 17-68 ng/mL.
Expression HEK293-derived Human CD40L protein Met113-Leu261 (Accession# P29965) with a His tag at the N-terminus.
GeneID 959
Accession P29965
PredictedSize 17 kDa
SDS-PAGE 17-19 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

The CD40 ligand (CD40L), also known as TRAP or CD154, is a member of the TNF superfamily of ligands. CD40L is primarily expressed on activated CD4+ T cells and on a small proportion of CD8+ T cells and platelets. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. It has been suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. The CD40/CD40L system is also involved in tumorigenesis. Its expression is tightly regulated, and abnormal levels of CD40L are associated with the pathogenesis of atheromatous plaque destabilization and thrombotic events. Multiple mutations in CD40LG gene have been identified that are associated with hyper-IgM immunodeficiency syndrome type 1.

References:

1. Elgueta R. et al. (2009). Immunol Rev. 229(1):152-172. 2. Rizvi M. et al. (2008). Trends Mol Med. 14(12):530-538. 3. Michel N A. et al. (2017). Front Cardiovasc Med. 4:40.